Syngene International Ltd

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, is currently navigating a complex technical landscape marked by a shift from sideways to mildly bearish momentum. Despite some bullish weekly indicators, monthly signals remain subdued, reflecting a cautious outlook for investors amid recent price declines and underperformance relative to benchmarks.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.85%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, reflecting cautious investor sentiment amid broader market challenges.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on its fundamentals, valuation, financial trends, and technical outlook.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, is currently navigating a complex technical landscape marked by a shift from sideways to mildly bearish momentum. Despite some bullish indicators on weekly charts, monthly signals remain subdued, reflecting a cautious outlook for investors amid recent price declines and mixed momentum readings.

Syngene International Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day decline of 0.83%, the stock’s technical parameters suggest a nuanced outlook for investors navigating the healthcare services sector.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

At Rs 518.55, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Syngene International Ltd locked at its upper circuit of 20% on 30 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Syngene International Ltd, a prominent player in the Healthcare Services sector, witnessed a significant spike in trading value on 30 April 2026, emerging as one of the most actively traded stocks by value. Despite a strong intraday rally and outperformance against its sector, the stock remains under a cautious rating outlook, reflecting a complex interplay of market enthusiasm and fundamental concerns.

Syngene International Ltd, a prominent player in the healthcare services sector, witnessed an extraordinary surge in trading volume on 30 Apr 2026, with over 75 lakh shares exchanging hands. This volume spike accompanied a robust price rally, as the stock outperformed its sector and broader market indices, signalling renewed investor interest despite a recent downgrade in its Mojo Grade.

Syngene International Ltd., the integrated contract research and manufacturing services provider, reported a dramatic rebound in quarterly net profit for Q4 FY26, posting ₹147.90 crores—a staggering 886.00% surge quarter-on-quarter from the anaemic ₹15.00 crores in Q3 FY26. However, this impressive sequential recovery masks a more sobering reality: profits declined 19.31% year-on-year from ₹183.30 crores in Q4 FY25, whilst the stock rallied 7.68% to ₹465.25 following the results announcement, reflecting investor relief at the sequential improvement despite persistent underlying challenges.

While the Sensex declined by 1.22% on 30 Apr 2026, Syngene International Ltd surged 10.18%, touching an intraday high of Rs 477.55. This 9.33-percentage-point outperformance over its Healthcare Services sector peers highlights a distinctly stock-specific rally amid a broadly weak market environment.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the most recent and relevant data to assess the company's outlook.

Syngene International Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a mild improvement in market sentiment, although fundamental concerns remain significant.

Syngene International Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a cautious outlook. Despite a recent 5.42% rise in the stock price to ₹435.65, the overall technical trend remains mildly bearish, underscoring the challenges facing this small-cap healthcare services company amid broader market dynamics.